Micancer Center S.L.P. — Clinical Trial Site

33 Registered trials

18 Currently recruiting

Organisation

Micancer Center S.L.P.

Location

Barcelona, Spain

Identifier

ORG-100044315

Address

Calle Del Doctor Roux 76 Planta 5, 08017, Spain

Departments

1605:Oncología
Cardiology
Clinical Trials
Digestive System
Endocrinology
Medical oncology
Oncología
oncología médica
Oncology
Pratia ES Sirius Barcelona – Clínica Tres Torres, Oncology
Servicio de Oncologia
Servicio de Oncología Médica
UOMI Cancer Center
UOMI Cancer Center - Oncology

Clinical trials at this site (33)

Search interface

A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L… Pending

2025-522818-23-00 Small Cell Lung Cancer (SCLC) 5
A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3… Pending

2025-523674-16-00 Metabolic Dysfunction-Associated Steatohepatitis (MASH) 5
A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F… Pending

2025-523675-39-00 Metabolic Dysfunction-Associated Steatohepatitis (MASH) 5
A study to test single and multiple doses of MER511 given to adults with Graves’ disease Pending

2025-523823-23-00 Graves’ disease 1
A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting

2025-523742-27-00 Advanced solid tumors 9 2026-04-28
A Study of Transition Regimens to KPL-387 Monotherapy in Participants with Well-Controlled Recurrent Pericarditis Recruiting

2025-523234-66-00 Well-Controlled Recurrent Pericarditis 4 2026-04-17
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me… Recruiting

2025-521919-39-00 Resected stage IIB, IIC, or III melanoma requiring adju 3 2026-02-10
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity … Recruiting

2025-521562-95-00 Previously Untreated Advanced (Unresectable or Metastat 5 2025-12-30
Effect of immunotherapy in patients with oligo-metastatic (limited number of metastases) non-small cell lung cancer after being treated with… Recruiting

2023-508741-40-00 Non-small cell lung cancer 10 2025-01-14
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
Kidney cancer Recruiting

2023-505605-16-00 Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) or p 7 2024-04-24
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
A Phase 3 study of Hetrombopag in patients with low blood platelet count (thrombocytopenia) caused by chemotherapy Recruiting

2025-524209-34-00 Chemotherapy induced thrombocytopenia 5 2026-05-20
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting

2024-517553-26-00 Advanced ALK-positive non-small cell lung cancer (NSCLC 5 2025-11-12
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas… Recruiting

2023-508112-35-00 ROS1-positive non-small cell lung cancer (NSCLC) with a 4 2025-04-15
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting

2024-514304-14-00 Advanced or Metastatic Non-squamous Non-Small Cell Lung 1 2024-10-08
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced… Recruiting

2023-503865-48-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 4 2024-02-16
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors… Recruiting

2024-514266-39-00 Advanced Non-Small Cell Lung Cancer (NSCLC) and Other S 7 2022-11-03
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Recruiting

2024-511793-71-00 Advanced ROS1-positive NSCLC and other advanced ROS1-po 7 2022-02-28
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem… Ended

2023-505773-32-00 Untreated Metastatic Non-Squamous Non-Small Cell Lung C 10 2025-03-25
Study of SKB264 to treat participants with advanced non-small cell lung cancer alone or as a combination treatment Ended

2023-507270-41-00 Advanced or Metastatic Non-small Cell Lung Cancer 4 2024-11-22